FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
Oppenheimer analyst Ling Wang reiterated an Outperform rating and $26 price target on Rockwell Medical Technologies (NASDAQ: RMTI) following the company Q3 updated. The analyst notes the company singed a signed a supply contract with one of the top four dialysis providers for Triferic, although... More
Rockwell Medical Technologies (NASDAQ: RMTI) reported Q3 EPS of ($0.05), $0.03 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.93 million.
For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.
... More
